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Nephronophthisis (NPHP), an autosomal recessive cystic
kidney disease, is the most frequent genetic cause for end-
stage renal failure in the first three decades of life. Mutations
in 13 genes (NPHP1-NPHP11, AHI1, and CC2D2A) cause NPHP
with ubiquitous expression of the corresponding proteins
consistent with the multiorgan involvement of NPHP-related
diseases. The genotype–phenotype correlation in these
ciliopathies can be explained by gene locus heterogeneity,
allelism, and the impact of modifier genes. In some NPHP-
related ciliopathies, the nature of the recessive mutations
determines disease severity. In order to define the
genotype–phenotype correlation more clearly, we evaluated
a worldwide cohort of 440 patients from 365 families with
NPHP-related ciliopathies, in whom both disease-causing
alleles were identified. The phenotypes were ranked in the
order of severity from degenerative to degenerative/
dysplastic to dysplastic. A genotype of two null alleles caused
a range of phenotypes, with an increasing order of severity of
NPHP1, NPHP3, NPHP4, NPHP5, NPHP2, NPHP10, NPHP6, to
AHI1. Only NPHP6 showed allelic influences on the
phenotypes; the presence of two null mutations caused
dysplastic phenotypes, whereas at least one missense allele
rescued it to a milder degenerative phenotype. We also
found nine novel mutations in the NPHP genes. Thus, our
studies have important implications for genetic counseling
and planning of renal replacement therapy.
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Nephronophthisis (NPHP) is an autosomal recessive cystic
kidney disease that represents the most frequent genetic cause
of end-stage renal disease (ESRD) in the first 3 decades of life.1
So far, 13 genes (NPHP1–NPHP11, AHI1, and CC2D2A) have
been identified that cause NPHP when mutated.2–15 Interest-
ingly, NPHP can occur with isolated kidney involvement or
in combination with diverse extrarenal manifestations. Spe-
cifically, it can be associated with: (i) retinal degeneration in
Senior–Løken syndrome (SLSN); (ii) cerebellar vermis aplasia
(CVA)/hypoplasia (CVH), retinal degeneration, and mental
retardation in Joubert syndrome (JBTS); and (iii) dysplastic
phenotypes of multiple organs leading to lethal Meckel–Gruber
syndrome (MKS). The genotype–phenotype correlation in
NPHP-related ciliopathies (NPHP-RC) seems to be governed
by three genetic mechanisms: gene locus heterogeneity, allelism,
and modifier genes. Although the ubiquitous expression of
NPHP proteins corresponds to the multiorgan involvement in
NPHP-RC, the pleiotropy of NPHP genes raises the importance
of allelism as the nature of the mutations can also determine
disease severity. Sometimes the presence of two null (protein-
truncating/nonsense) mutations causes severe, early-onset,
dysplastic, multiorgan phenotypes, whereas missense muta-
tions result in mild, late-onset, degenerative phenotypes with
limited organ involvement. To test whether this is universally
true, in this study we evaluated the genotype–phenotype
correlation in 440 individuals from 365 families of an
international cohort with NPHP-RC, in whom we detected
both recessive mutations in 13 different NPHP genes
(NPHP1–NPHP11, AHI1, and CC2D2A). Whereas we had
published many of these mutations previously,3,6–11,14–21 in this
study, we report nine novel mutations in NPHP2, NPHP3,
NPHP4, NPHP5, NPHP6, NPHP8, and AHI1. As for
NPHP7 and NPHP9 there were only single families with
mutations available, we did not include these genes in our
genotype–phenotype study.
RESULTS
Analysis of genotype–phenotype correlation
NPHP1. In 248 individuals from 235 families, the cause of
the disease was two recessive NPHP1 mutations, with 93%
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(219 families) being the homozygous deletion of NPHP1. The
patients exhibited a ‘typical’ juvenile NPHP (ESRD X4
years) and most of them (180/235 families, 76.5%) had
isolated kidney involvement. In 55 families, extrarenal
manifestations were noted: specifically, 24 had central
nervous system (CNS) defects (oculomotor apraxia type
Cogan, mental retardation, locomotive disorders, CVA,
developmental delay, porencephaly, hydrocephalus, and
epileptic seizure) and 27 had eye involvement (tapeto-retinal
degeneration (TRD), optic nerve atrophy, and pigmented
fundus). Two families exhibited liver fibrosis and two had
heart anomalies (hypertrophic non-obstructive cardiomyo-
pathy and aortic stenosis).
NPHP2/INVS. In our cohort of 12 families (18 patients)
with recessive NPHP2 mutations, 10 carried two nonsense
mutations, 1 had two missense mutations, and 1 was
compound heterozygous for one nonsense and one missense
mutation (Supplementary Table S1 online). The renal
phenotype always showed infantile ESRD (at p4 years)
regardless of the mutation type. In contrast to other forms of
NPHP, the patients exhibited enlarged (dysplastic) cystic
kidneys. In addition, the phenotypes of the patients with two
nonsense mutations were not comparable with each other as
they varied from isolated NPHP to JBTS. Extrarenal
manifestations were present in 5 of 12 families and included
dysplastic phenotypes of the eye (optic nerve atrophy), CNS
(hydrocephalus), and the heart (situs inversus, ventricular
septal defect, and aortic coarctation). We had one family each
with a degenerative phenotype of the eye (TRD) and the
heart (hypertrophic cardiomyopathy), and one family with
the unusual phenotype of asthma.
NPHP3. Among our cohort of eight families (13 patients)
with recessive NPHP3 mutations, four carried two nonsense
alleles, two were homozygous for splice site mutations, one
was compound heterozygous for one nonsense and one
missense allele, and one carried one nonsense and one splice
site allele (Supplementary Table S2 online). The renal
phenotype always showed ESRD onset between 3 and 13
years regardless of the mutation type, except A1633 (MKS)
who passed away at day 3. Extrarenal manifestations were
found in four of eight families and included dysplastic
phenotypes of the CNS (CVH, molar tooth sign (MTS), and
mental retardation) and the heart (atrial septal defect,
pulmonary hypoplasia, situs ambiguous, and pulmonary
valve stenosis). Two families, with one nonsense mutation
and one missense or splice site mutation, had the
degenerative phenotype of liver fibrosis.
NPHP4. Among our cohort of 22 families (42 patients)
with recessive NPHP4 mutations, 16 carried two nonsense
alleles, two had two missense alleles, one was homozygous for
a splice site mutation, two were compound heterozygous for
one nonsense and one missense mutation, and one was
compound heterozygous for one nonsense and one splice site
allele (Supplementary Table S3 online). The renal phenotype
always showed juvenile ESRD regardless of the mutation
type. Interestingly, in two families (one homozygous for a
nonsense mutation and the other compound heterozygous
for missense mutations) enlarged kidneys were observed.
Extrarenal manifestations were present in 10 of 22 families
and included dysplastic phenotypes of the eye (coloboma and
Leber’s congenital amaurosis) and the CNS (mental retarda-
tion and developmental delay). There were six families with
degenerative phenotypes of the eye (TRD and papillorenal
syndrome) and the liver (liver fibrosis), and three with
deafness or hearing impairment. There were also the unusual
phenotypes of splenomegaly and chronic bronchitis. Inter-
estingly, eight families with two nonsense mutations
displayed renal manifestations only.
NPHP5/IQCB1. In our cohort of 25 families (33 patients)
with recessive NPHP5 mutations, 23 had two nonsense
mutations and two were homozygous for obligatory splice
site mutations (Supplementary Table S4 online). Interest-
ingly, despite having two null mutations, the phenotypes of
the patient never showed dysplasia in any organ; rather, they
always had degenerative phenotypes involving both kidneys
and eyes. The renal phenotype showed juvenile ESRD and
was always associated with early-onset retinal degeneration
(o4 years). One patient had epileptic seizure and one
exhibited syndactyly. There was also the unusual phenotype
of asthma and one patient had carcinoma in the right kidney
and a tumor in the left ovary.
NPHP6/CEP290. Among 19 families (26 patients) with
recessive NPHP6 mutations, 14 carried two nonsense
alleles, one had two missense alleles, two were homozygous
for obligatory splice site mutations, and two were compound
heterozygous for one nonsense and one missense or splice
site mutation, respectively (Supplementary Table S5 online).
All patients developed juvenile ESRD, with two exceptions of
infantile ESRD; two patients had enlarged kidneys. All
patients with NPHP6 mutations showed extrarenal pheno-
types, which included dysplastic phenotypes of the eye (optic
nerve atrophy, Leber’s congenital amaurosis, and coloboma),
the CNS (CVA, CVH, mental retardation, microcephaly,
hydrocephalus, and encephalocele occipital), and degenera-
tive phenotypes such as TRD, liver fibrosis, and epileptic
seizure.
NPHP8/RPGRIP1L. In eight families (12 patients) with
recessive NPHP8 mutations, five had two missense mutations
and three were compound heterozygous for one nonsense
and one missense mutation (Supplementary Table S6 online).
We never found any patient with two nonsense mutations.
The renal phenotype always showed juvenile onset of ESRD
regardless of the mutation type. Six families had dysplastic
phenotypes of the CNS (Dandy–Walker malformation, CVA,
developmental delay, encephalocele occipital, MTS, strabis-
mus, and ptosis), four had oculomotor apraxia type Cogan,
and there were two cases with polydactyly, which is a cardinal
symptom of patients with Bardet–Biedl syndrome but very
rarely occurs in NPHP-RC.
NPHP10/SDCCAG8. In seven families (12 patients) with
recessive NPHP10 mutations, five carried two nonsense
mutations, one was homozygous for an obligatory splice site
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mutation, and one was compound heterozygous for a
nonsense and a splice site allele (Supplementary Table S7
online). Similar to NPHP5, the phenotypes of patients with
NPHP10 mutations were always degenerative involving both
kidneys and eyes, but occasionally additional extrarenal
manifestations were present. Regardless of the mutation type,
all patients in this cohort had juvenile ESRD. Four patients
presented with extrarenal manifestations including degen-
erative phenotype of the CNS (mental retardation, peripheral
neuropathy, and cystic brain lesion), generalized seizures,
Bardet–Biedl syndrome-like obesity, and hypogenitalism. One
patient showed the unusual phenotype of polycystic ovary
syndrome.
NPHP11/TMEM67/MKS3. In our 20 families (26 patients)
with recessive NPHP11 mutations, 12 had two missense
mutations, six were compound heterozygous for one
nonsense and one missense mutation, and two carried one
splice site and one missense mutations (Supplementary Table
S8 online). In NPHP11, we never detected any patient with
two nonsense mutations. Almost all patients exhibited
juvenile NPHP, except F278 who exhibited infantile ESRD.
In our cohort, all patients exhibited extrarenal manifesta-
tions, which mostly included dysplastic phenotypes of the
CNS (CVH, CVA, brain atrophy, cerebellar hypoplasia,
Dandy–Walker malformation, developmental delay, MTS,
oculocerebral disease, mental retardation, strabismus,
psychomotor retardation, and ptosis) and the eye (coloboma
and optic nerve atrophy), and degenerative liver phenotypes
(liver fibrosis, cholangiopathy, and hepatomegaly). Three
patients had TRD, one had dysplastic heart phenotype
(subvalvular aortic stenosis), and one had dysplastic liver
phenotype (cholangiodysplasia). There were also the unusual
phenotypes of splenomegaly and Ehlers–Danlos syndrome,
and one patient had polydactyly.
AHI1. In our cohort of six families (seven patients) with
recessive AHI1 mutations, five had two nonsense mutations
and one was homozygous for a splice site mutation
(Supplementary Table S9 online). All patients had juvenile
NPHP, except F400 who did not have any renal involvement.
Extrarenal manifestations were present in all cases and
included dysplastic phenotypes of the CNS (MTS and
psychomotor developmental delay) and the eye (coloboma).
Three patients had TRD, two had tachypnea, and ataxia was
reported in one patient.
CC2D2A. In our cohort of three families (three patients)
with recessive CC2D2A mutations, all patients were com-
pound heterozygous for one nonsense and one missense
mutation (Supplementary Table S10 online). We never
detected any patient with two nonsense mutations, although
two of three patients had been diagnosed with MKS. All
patients showed dysplastic renal phenotypes, one with
infantile NPHP. Extrarenal manifestations were present in
all patients and included dysplastic phenotypes of the CNS
(CVH, mental retardation, and encephalocele occipital), the
liver (hepatic developmental defects), and the bone (disarray
of bone–cartilage junctions).
Identification of novel mutations in NPHP2, NPHP3, NPHP4,
NPHP5, NPHP6, NPHP8, and AHI1
Two patients (families A1423 and A2035) with infantile
NPHP (ESRD 12 and 19 months, respectively) were
homozygous for a novel nonsense mutation c.2716G4T
(p.E906X) in NPHP2.
In two patients, two novel mutations were detected in
NPHP3: A1633, who passed away at day 3, had a homozygous
frameshift mutation c.3702delA (p.K1234fsX1246), and
A1937 (ESRD 8 years 7 months) was homozygous for
p.3235C4T (p.Q1079X). Notably, A1633 exhibited an
MKS-like phenotype, characterized by CVH, atrial septal
defect, double-outlet right ventricle, pulmonary valve
stenosis, pulmonary hypoplasia, asplenia, situs ambiguous,
and congenital contractures, whereas A1937 showed char-
acteristic features of JBTS including MTS, CVH, and mental
retardation.
One novel NPHP4mutation was detected in A2324 (ESRD
7 years). The patient was homozygous for c.2618_2619insA
(p.H873fsX886) and had mental retardation. Interestingly,
one sibling with this mutation exhibited TRD and was
diagnosed with oculomotor apraxia type Cogan.
Two novel NPHP5 mutations were detected in two
patients with SLSN. F353 was found to be homozygous
for c.1363C4T (p.R455X) and A1538 was homozygous for
the obligatory splice site mutation c.1130-1G4C. Interest-
ingly, one sibling with the splice site mutation also had
syndactyly.
For NPHP6, NPHP8, and AHI1, one novel mutation
was identified in each case. A2182 (juvenile ESRD) was
homozygous for the obligatory splice site mutation
c.2367þ 1G4T in NPHP6 and displayed TRD, mental
retardation, and microcephaly. A1685, with two affected
siblings (ESRD 15 and 17 years), was homozygous for a
missense mutation c.2450A4G (p.Y817C) in NPHP8 and
had mental retardation and oculomotor apraxia type Cogan.
A2045 (ESRD 17 years) carried a homozygous deletion
c.2172delA (p.I724fsX729) in AHI1.
DISCUSSION
In this study, we have evaluated the genotype–phenotype
correlation in a cohort of 440 patients from 365 families with
NPHP-RC in whom both mutations were identified. The
effect of different NPHP-RC genes on ‘disease phenotype’ is
summarized in Table 1, and Figure 1 represents images that
are descriptive of the pathological features. As for all patients,
mutation screening was not done for all NPHP genes, thus
we cannot conclude the influence of the modifier genes on a
phenotype. Mental retardation has been marked as ‘dysplas-
tic’ in case of JBTS patients, who are known to have
congenital dysplasia of CNS, and as ‘degenerative’ in patients,
who did not have any dysplasia in the brain or any other
organ and rather showed degenerative phenotypes only. We
observed that a genotype of two null alleles causes
phenotypes in the following increasing order of severity:
NPHP1, NPHP4, NPHP5, NPHP2, NPHP10, NPHP6 to
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AHI1. For NPHP8 and NPHP11, no patient was homozygous
for two null mutations, most likely because our cohort did
not contain a significant number of MKS patients.
Deleterious recessive mutations in NPHP1 caused the
mildest disease phenotype compared with the null mutations
in other known NPHP-causing genes, resulting mostly in
isolated kidney disease. However, about 23.4% (55/235
families) of these patients present with extrarenal organ
manifestations, some of which are even dysplastic. We
speculate that additional mutations in NPHP-related ‘modi-
fier’ genes might contribute to the development of these
extrarenal symptoms as proposed previously.22
In our cohort, all patients with NPHP2 mutations showed
‘infantile ESRD’ (i.e., onset o4 years) with a dysplastic
kidney phenotype regardless of the mutation type (i.e.,
nonsense/missense); however, not all the patients with
homozygous null mutations showed extrarenal manifesta-
tions, which corroborate the previous observations.10,19,23,24
We conclude that NPHP2 mutations result in ‘infantile
NPHP’ with rare extrarenal manifestations (Supplementary
Table S1 online). According to Tory et al,24 sometimes
different phenotypes were noted for the same mutation,
which indicates the possibility of the presence of additional
mutations in modifier genes.
No genotype–phenotype correlation was evident for
NPHP3 and NPHP4 (Supplementary Tables S2, S3 online),
as the phenotypes of the families with two nonsense
mutations were not similar. For NPHP3, the phenotypes of
A1633 (MKS) and A1937 (JBTS) were more severe compared
with F86 and A14 (isolated NPHP). In contrast to some
earlier reports,24,25 we did not observe an MKS-like
phenotype in all patients with complete loss of NPHP3
function (two null mutations). We conclude that NPHP3
mutations can have diverse effects ranging from infantile
ESRD and severe extrarenal manifestations to juvenile ESRD
with isolated kidney phenotype. Notably, in our cohort,
dysplastic extrarenal manifestations were seen only in
patients with two nonsense (null) mutations. For NPHP4,
extrarenal manifestations were not always present and we
conclude that NPHP4 mutations always result in juvenile
ESRD with frequent (7/22 families,B32%) eye involvement.
NPHP5 mutations always resulted in dimorphic disease
(SLSN) with juvenile onset NPHP and infantile onset of
TRD. Hence, this gene can be stated as a ‘classic’ SLSN-
causing gene (Supplementary Table S4 online). Similarly,
NPHP10 mutations also resulted in SLSN in most of the
patients, often involving extrarenal manifestations in addi-
tion (Supplementary Table S7 online).
In our cohort, 17 of 19 families (B90%) with NPHP6
mutations had juvenile NPHP with extrarenal manifesta-
tions, and for this gene we found strong allelic influence on
the phenotypes (Supplementary Table S5 online). In the
families with less than two null alleles, none of the patients
showed any dysplastic phenotype and almost never more
than two organs were involved. In contrast, in patients
with two null mutations always more than two organs
were involved, and the patients showed at least one dys-
plastic phenotype. Notably, in the previous reports, the
genotype–phenotype correlation was not clear for NPHP6, as
phenotypes of the patients with two null mutations varied
from MKS to JBTS to Leber’s congenital amaurosis.14,26,27 We
speculate that the reason for this observation might be
Table 1 | Summary of genotype–phenotype correlation
Kidney Eye CNS Liver Heart
2 null
alleles
<2 null
alleles
2 null
alleles
<2 null
alleles
2 null
alleles
<2 null
alleles
2 null
alleles
<2 null
alleles
2 null
alleles
<2 null
alleles
NPHP1 (226) 1 (0.4%) +
219 (96.9%) 6 (2.6%)
3 (1.3%) +
20 (8.8%) 1 (0.4%)
15 (6.6%) +
7 (3%) 1 (0.4%) 2 (0.8%)
–
2 (0.8%)
–
NPHP2 (12) 10 (83.3%) 2 (16.6%) 1 (8.3%) +
1 (8.3%)
– 1 (8.3%) – – – 2 (16.6%) +
1 (8.3%)
–
NPHP3 (5) 1 (20%) +
3 (60%) 1 (20%)
– – 2 (40%) – –
1 (20%)
1 (20%) –
NPHP4 (20)
16 (80%) 4 (20%)
3 (15%) +
3 (15%) 1 (5%)
2 (10%) –
1 (5%) 1 (5%)
– –
NPHP5 (23)
23 (100%)
– 1 (4.3%) +
22 (95.6%)
– – – – – – –
NPHP6 (16) 1 (6.2%) +
13 (81.2%)
1 (6.2%) +
1 (6.2%)
8 (50%) +
4 (25%)
1 (6.2%) +
1 (6.2%)
11 (68.7%) 1 (6.2%)
1 (6.2%)
– – –
NPHP8 (8) – 2 (25%) +
5 (62.5%)
– – – 6 (75%) – 1 (12.5%) – –
NPHP10 (5)
5 (100%)
–
4 (80%)
–
1 (20%)
– – – – –
NPHP11 (18) – 1 (5.5%) +
17 (94.4%)
– 7 (38.5%) +
2 (11.1%)
– 16 (88%) – 1 (5.5%) +
13 (71.5%)
– 1 (5.5%)
AHI1 (5) 1 (20%)
3 (60%)
– 1 (20%) +
2 (40%)
– 4 (80%) – – – – –
CC2D2A (3) – 3 (100%) – – – 3 (100%) – – – 1 (33.3%)
Gene
(families)
Abbreviation: CNS, central nervous system.
As splice site mutations can have varying effects, families with splice site mutations were not included in the table. Numbers of patients with dysplastic or degenerative
phenotypes are marked with red or green fonts, respectively.
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the fact that the domain of the protein being mutated is
crucial.
According to the literature, complete loss of function of
NPHP8 leads to MKS, and two missense mutations lead to a
degenerative phenotype of kidneys and eyes.3 We have one
MKS patient in our cohort, but the patient is compound
heterozygous for a nonsense and a missense mutation.
Hence, we conclude that NPHP8 mutations cause severe
phenotypes irrespective of the mutation type, because in our
cohort at least six of eight families have dysplastic phenotypes
of the CNS (Supplementary Table S6 online). Similarly, any
NPHP11 mutation leads to severe phenotypes (Supplemen-
tary Table S8 online). In our cohort, patients with two
missense mutations in NPHP11 almost always developed
liver fibrosis (16/20 families), CVA/CVH (10/20 families),
and mental retardation (14/20 families). In addition, retinal
coloboma was present in 8 families.
For AHI1, we observed that all our patients with two
nonsense mutations have JBTS (Supplementary Table S9
online), which is concordant with other reports.28–30 There-
fore, AHI1 can be classified as a ‘JBTS causing gene’, as all the
patients with mutations in this gene exhibit JBTS with the
pathognomonic feature of the ‘molar tooth sign’ seen by
magnetic resonance imaging. However, for CC2D2A, the
number of patients is too small to draw any conclusion on
the genotype–phenotype correlation. In our cohort of three
patients, CC2D2A mutations always lead to severe pheno-
types; therefore, it is most likely that CC2D2A is an MKS or
JBTS causing gene rather than an isolated NPHP gene. Thus,
according to the data obtained from our cohort, we suggest a
genetic analysis pathway based on the presence of frequent
and less frequent phenotypes (Figure 2). We conclude that
the ‘gene locus heterogeneity’ is the prime factor in
determining the disease phenotype, whereas ‘allelism’ might
be somewhat important only for certain genes such as
NPHP6, NPHP8, and NPHP11.
MATERIALS AND METHODS
Patients
We collected blood samples, pedigrees, and clinical information with
informed consent (http://www.renalgenes.org) from a worldwide
R L
Figure 1 |Representative images of degenerative and
dysplastic clinical features observed in nephronophthisis
(NPHP)-related ciliopathies. (a) Renal ultrasound from an
individual with (degenerative) NPHP. Cysts occur only at the
corticomedullary junction and are marked with arrowheads.
(b) Renal ultrasound from an individual with (dysplastic)
Meckel–Gruber syndrome (MKS, A1633-22). Cysts occur
throughout an enlarged kidney and are marked with arrowheads.
(c) Autopsy kidney specimen from a fetus with MKS showing
bilateral enlarged kidneys interspersed with small, pinhead-sized
cysts. (d) Renal histology showing cystic dysplastic kidneys with
marked interstitial fibrosis in MKS. (e) Ophthalmoscopy reveals
retinitis pigmentosa in the right eye of a patient with
(degenerative) Senior–Løken syndrome. (f) Left eye of an NPHP
patient with diffuse retinal atrophy with markedly pale discs and
enlarged cup. (g) Liver histology showing dysgenesis of the
hepatic portal triad with hyperplastic biliary ducts and congenital
hepatic fibrosis. (h) Brain magnetic resonance imaging with ‘molar
tooth sign’ (marked with a circle) demonstrating cerebellar vermis
hypoplasia, a dysplastic phenotype observed in a JBTS patient.
(i) Chest X-ray image of a patient showing situs inversus.
(j) Postaxial hexadactyly in an MKS fetus.
Kidney International (2011) 80, 1239–1245 1243
M Chaki et al.: Genotype–phenotype correlation in nephronophthisis o r ig ina l a r t i c l e
cohort of 365 families with MKS, JBTS, SLSN, or isolated NPHP.
Approval for studies on human subjects was obtained from the
University of Michigan Institutional Review Board. In all patients,
the diagnosis of NPHP was based on one or more of the following
criteria: (i) clinical course with characteristic clinical signs of
polyuria, polydipsia, anemia, and growth retardation; (ii) presence
of chronic renal failure; (iii) renal ultrasound or renal biopsy
compatible with the diagnosis of NPHP as judged by a pediatric
nephrologist; (iv) pedigree compatible with autosomal recessive
inheritance. Neurological criteria for JBTS were based on the
following clinical hallmarks of this cerebello-oculo-renal syndrome:
MTS or diagnosis of JBTS by a neurologist (pediatric) or geneticist.
In addition, associated JBTS symptoms were recorded: nervus
opticus or retinal coloboma, TRD, CVA/CVH, ataxia, and periodic
apnea/tachypnea. The diagnosis of SLSN was based on the presence
of NPHP in association with TRD.
Mutation analysis of NPHP1–NPHP11, AHI1, and CC2D2A
Genomic DNA from peripheral blood samples was extracted by
standard methods. Mutations were detected by homozygosity
mapping31 followed by PCR amplification of respective exons with
flanking primers and direct sequencing of each amplicon using the
dideoxy chain termination method on an Applied Biosystems (ABI)
capillary sequencer (Applied Biosystems, Foster City, CA). Resulting
sequences were aligned and evaluated by Sequencher (version 3.8)
software (Gene Codes Corporation, Ann Arbor, MI). Novel
mutations were found to be absent from at least 90 ethnically
matched healthy controls.
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